← Back to Search

THRIVE App for Breast Cancer (THRIVE Trial)

N/A
Waitlist Available
Led By Ilana Graetz, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 12
Awards & highlights

THRIVE Trial Summary

This study is evaluating whether an app which provides tailored feedback to patients may help improve their quality of life and adherence to treatment.

Eligible Conditions
  • Breast Cancer

THRIVE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to month 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adjuvant Endocrine Therapy (AET) Medication Adherence
Secondary outcome measures
19 Item Endocrine Symptom Subscale (ESS-19) Score of the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)
Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Symptoms Score
Short Form Health Survey (SF-12) Mental Component Summary (MCS) Score
+1 more

THRIVE Trial Design

3Treatment groups
Active Control
Group I: THRIVE AppActive Control1 Intervention
Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
Group II: THRIVE App+FeedbackActive Control2 Interventions
Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
Group III: Usual CareActive Control1 Intervention
Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,642 Previous Clinical Trials
2,563,598 Total Patients Enrolled
28 Trials studying Breast Cancer
3,028 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,692 Previous Clinical Trials
40,929,671 Total Patients Enrolled
941 Trials studying Breast Cancer
1,543,396 Patients Enrolled for Breast Cancer
West Cancer CenterOTHER
4 Previous Clinical Trials
291 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
THRIVE Breast Cancer App Study
Ilana Graetz 2018. "THRIVE Breast Cancer App Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03592771.
~47 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top